scholarly journals Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7134
Author(s):  
Richard Kwamla Amewu ◽  
Patrick Opare Sakyi ◽  
Dorcas Osei-Safo ◽  
Ivan Addae-Mensah
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
The Body ◽  
Vascular Endothelial ◽  
Anticancer Compounds ◽  
Biological Targets ◽  
Anticancer Properties ◽  
Naturally Occurring ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Cancer is a complex group of diseases initiated by abnormal cell division with the potential of spreading to other parts of the body. The advancement in the discoveries of omics and bio- and cheminformatics has led to the identification of drugs inhibiting putative targets including vascular endothelial growth factor (VEGF) family receptors, fibroblast growth factors (FGF), platelet derived growth factors (PDGF), epidermal growth factor (EGF), thymidine phosphorylase (TP), and neuropeptide Y4 (NY4), amongst others. Drug resistance, systemic toxicity, and drug ineffectiveness for various cancer chemo-treatments are widespread. Due to this, efficient therapeutic agents targeting two or more of the putative targets in different cancer cells are proposed as cutting edge treatments. Heterocyclic compounds, both synthetic and natural products, have, however, contributed immensely to chemotherapeutics for treatments of various diseases, but little is known about such compounds and their multimodal anticancer properties. A compendium of heterocyclic synthetic and natural product multitarget anticancer compounds, their IC50, and biological targets of inhibition are therefore presented in this review.

Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and the epidermal growth factor

Blood ◽  
2000 ◽  
Vol 96 (5) ◽  
pp. 1772-1781
Author(s):  
Lixin Liu ◽  
Jo C. Tsai ◽  
William C. Aird
Keyword(s):  
Skeletal Muscle ◽  
Vascular Endothelial Growth Factor ◽  
Endothelial Cells ◽  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Mrna Levels ◽  
Vascular Endothelial ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Egr-1 is a transcription factor that couples short-term changes in the extracellular milieu to long-term changes in gene expression. In cultured endothelial cells, the Egr-1 gene has been shown to respond to a variety of extracellular signals. However, the physiological relevance of these findings remains unclear. To address this question, the growth factor-mediated response of the Egr-1 gene under in vivo conditions was analyzed. To that end, either vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF) was injected into the intraperitoneal cavity of mice. Growth factors were delivered to all tissues examined, as evidenced by the widespread distribution of I125-labeled growth factors and the phosphorylation of their respective receptors. In Western blot analyses of whole-tissue extracts, Egr-1 protein levels were shown to be induced in the heart, brain, liver, and spleen of VEGF-treated mice, and in the heart, lung, brain, liver and skeletal muscle of EGF-treated animals. Changes in Egr-1 levels did not correlate with changes in receptor phosphorylation or ERK1/2 phosphorylation. In Northern blot analyses, VEGF induced Egr-1 mRNA levels in all tissues examined except lung and kidney, whereas EGF led to increased transcripts in all tissues except kidney. In immunofluorescence studies, VEGF induced Egr-1 in microvascular endothelial cells of the heart and liver, and EGF induced Egr-1 in the microvascular bed of skeletal muscle. Taken together, these results suggest that the Egr-1 gene is differentially regulated in response to systemically administered VEGF and EGF.

Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and the epidermal growth factor

Blood ◽  
2000 ◽  
Vol 96 (5) ◽  
pp. 1772-1781 ◽  
Author(s):  
Lixin Liu ◽  
Jo C. Tsai ◽  
William C. Aird
Keyword(s):  
Skeletal Muscle ◽  
Vascular Endothelial Growth Factor ◽  
Endothelial Cells ◽  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Mrna Levels ◽  
Vascular Endothelial ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Abstract Egr-1 is a transcription factor that couples short-term changes in the extracellular milieu to long-term changes in gene expression. In cultured endothelial cells, the Egr-1 gene has been shown to respond to a variety of extracellular signals. However, the physiological relevance of these findings remains unclear. To address this question, the growth factor-mediated response of the Egr-1 gene under in vivo conditions was analyzed. To that end, either vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF) was injected into the intraperitoneal cavity of mice. Growth factors were delivered to all tissues examined, as evidenced by the widespread distribution of I125-labeled growth factors and the phosphorylation of their respective receptors. In Western blot analyses of whole-tissue extracts, Egr-1 protein levels were shown to be induced in the heart, brain, liver, and spleen of VEGF-treated mice, and in the heart, lung, brain, liver and skeletal muscle of EGF-treated animals. Changes in Egr-1 levels did not correlate with changes in receptor phosphorylation or ERK1/2 phosphorylation. In Northern blot analyses, VEGF induced Egr-1 mRNA levels in all tissues examined except lung and kidney, whereas EGF led to increased transcripts in all tissues except kidney. In immunofluorescence studies, VEGF induced Egr-1 in microvascular endothelial cells of the heart and liver, and EGF induced Egr-1 in the microvascular bed of skeletal muscle. Taken together, these results suggest that the Egr-1 gene is differentially regulated in response to systemically administered VEGF and EGF.

An Optimized Extract, Named Self-Growth Colony, from Platelet-Rich Plasma Shows Robust Skin Rejuvenation and Anti-Ageing Properties: A Novel Technology in Development of Cosmetics

2021 ◽  
pp. 1-12
Author(s):  
Gallant Kar Lun Chan ◽  
Maggie Suisui Guo ◽  
Diana Kun Dai ◽  
Queenie Wing Sze Lai ◽  
Kelly Wing Chi Fung ◽  
...  
Keyword(s):  
Wound Healing ◽  
Growth Factors ◽  
Growth Factor ◽  
Platelet Rich Plasma ◽  
Vascular Endothelial ◽  
Skin Rejuvenation ◽  
Platelet Factor ◽  
Novel Technology ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

<b><i>Introduction:</i></b> Inspired by application of platelet-rich plasma (PRP) in skin treatment during injuries, an extracting method was developed here to recover high amounts of cytokines and growth factors from PRP; this prepared extract was named as self-growth colony (SGC). <b><i>Methods:</i></b> In optimization of SGC preparation, various parameters were tested, for example, centrifugation force, freeze-thaw, sonication, and inclusion of calcium chelator. The amounts of cytokines and growth factors, including platelet factor 4, β-thromboglobulin, epidermal growth factor, vascular endothelial growth factor, platelet-derived growth factor, were measured by ELISA assay. <b><i>Results:</i></b> By comparing to PRP, the prepared SGC contained a significant higher amount of measured growth factors. In addition, the degradation of growth factors within SGC during the storage was calibrated, which showed better stability as compared to that of PRP preparation. Having possible application in skin care, the optimized SGC was chemically standardized by using the enrichment of growth factors. Application of SGC in cultured keratinocytes stimulated the wound healing of injured cultures. In line to this notion, SGC was applied onto human skin, and thereafter the robust improvement of skin properties was revealed. <b><i>Conclusions:</i></b> The potential application of SGC in treating skin rejuvenation and ageing, as well as its elaborated application for medical purpose, that is, wound healing, was illustrated.

scholarly journals Production and reception of the growth factor in the placenta during the physiological pregnancy and the pregnancy, complicated with gestosis

2014 ◽  
Vol 18 (2 (70)) ◽  
Author(s):  
O. A. Kuzmina
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
First Trimester ◽  
Vascular Endothelial ◽  
Elisa Method ◽  
Angiogenic Growth Factors ◽  
Epidermal Growth ◽  
Physiological Values ◽  
Endothelial Growth Factor ◽  
Normal Gestation

30 women with physiological pregnancy and 28 women with gestosis were examined. In the early chorion obtained after abortion and on the full-term placenta the content of the epidermal growth factor (EGF), vascular-endothelial growth factor (VEGF) and their receptors were studied by means of the ELISA method. In the process of normal gestation the increase of the placental production both of the EGF and VEGF was found. During the pregnancy complicated with gestosis and miscarriage in the first trimester the content of EGF and its receptor was lower compared to the physiological values. For VEGF and its receptor opposite changes were found: the increase of quantity of the growth factor and the decrease of its receptor. In the case of gestosis and term pregnancy the content of the both growth factors and their receptors was lower than in controls. The revealed changes in production of the angiogenic growth factors and their receptors in the placenta may have the pathogenic importance in the development of gestosis.

scholarly journals Salivary growth factors in patients with chronic periodontitis

2021 ◽  
Vol 102 (5) ◽  
pp. 636-641
Author(s):  
V V Bazarnyi ◽  
L G Polushina ◽  
E A Sementsova ◽  
A Yu Maksimova ◽  
E N Svetlakova ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factors ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Chronic Periodontitis ◽  
Vascular Endothelial ◽  
Nerve Growth ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Aim. To determine the clinical value of the growth factors concentration in the oral fluid in patients with mild chronic periodontitis. Methods. A prospective study including 30 patients with chronic periodontitis and 20 healthy volunteers was conducted. The diagnosis was made based on standard clinical and radiological criteria. Nerve growth factor (NGF-), hepatocyte growth factor (HGF), epidermal growth factor (EGF), vascular endothelial growth factor A (VEGF-A), platelet-derived growth factor BB (PDGF-BB) were determined in oral fluid samples by using multiparametric fluorescence analysis with magnetic microspheres (xMAP technology, Luminex 200, USA). Statistical analysis was performed using nonparametric measures: median (Me) and interquartile range (Q1, Q3). Receiver operating characteristic (ROC) analysis was used to determine the clinical value of the parameters. Results. The chronic periodontitis was accompanied by an increase in the level of nerve growth factor- by 2.2 times, epidermal growth factor by 3 times, vascular endothelial growth factor A by 1.9 times (p 0.05) compared with the control. The platelet-derived growth factor BB concentration did not change. Using the ROC analysis, diagnostic sensitivity and diagnostic specificity of the studied parameters were determined: 89.1 and 91.1% for nerve growth factor , 92.3 and 96.1% for epidermal growth factor, 87.1 and 95.3% for vascular endothelial growth factor A, respectively. Conclusion. Salivary growth factors (nerve growth factor , epidermal growth factor, vascular endothelial growth factor A) can be considered as potential biomarkers of mild chronic periodontitis.

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document